AllianzIM美國股票緩衝10主動型ETF-9月 SEPT 深 滬
已收盤 05-08 16:00:00 美东时间
36.925
+0.105
+0.29%
華盛通- 最 高36.96
- 今 開36.88
- 成交量 20.90万股
- 最 低 36.87
- 昨 收 36.82
- 總市值 1.06亿
- 52周最高 36.96
- 市盈率 靜 --
- 換手率 7.27%
- 52周最低 29.85
- 委 比 -60.00%
- 總股本 287.50万
- 歷史最高 36.96
- 量 比 18.72
- 振 幅 0.24%
- 歷史最低 23.42
- 每 手 1
- 風險率 1.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多BRIEF-Nintendo Co: To Increase Nintendo Switch 2 Prices in Japan, U.S., Canada And Europe
BRIEF-Nintendo Co: To Increase Nintendo Switch 2 Prices in Japan, U.S., Canada And Europe May 8 (Reuters) - Nintendo Co Ltd 7974.T : TO REVISE MANUFACTURER’S SUGGESTED RETAIL PRICES OF JAPANESE-LANGUAGE NINTENDO SWITCH 2 SYSTEM TO 59,980 YEN FROM 49,980 YEN NINTENDO CO - ALSO PLANNING PRICE INCREASE
05-08 14:37
MORGAN STANLEY EXPECTS US FED TO KEEP INTEREST RATES UNCHANGED IN 2026 VS PRIOR FORECAST OF RATE CUTS IN SEPTEMBER AND DECEMBER
REFILE-Morgan Stanley expects Fed to hold rates in 2026 Corrects date to April 30 April 30 (Reuters) - Morgan Stanley expects the U.S. Federal Reserve to leave interest rates unchanged in 2026, citing still-elevated inflation and recent data pointing to economic resilience, it said in a note dated W
04-30 11:54
UBS RAISES BRENT CRUDE OIL FORECAST TO $100/BBL BY END OF JUNE, $95/BBL BY END OF SEPTEMBER, AND $90/BBL BY END OF DECEMBER
REFILE-UBS raises Brent oil price forecasts as Strait of Hormuz disruptions persist Corrects typographical error in headline April 13 (Reuters) - UBS on Monday raised its Brent oil price forecasts for the remaining quarters of 2026 and first quarter of 2027 as flows through the Strait of Hormuz cont
04-13 18:20
BRIEF-BAT Appoints Dragos Constantinescu As CFO
BRIEF-BAT Appoints Dragos Constantinescu As CFO April 9 (Reuters) - British American Tobacco PLC BATS.L : BRITISH AMER.TOBACCO - DIRECTORATE CHANGE BAT - APPOINTS DRAGOS CONSTANTINESCU AS CFO AND EXECUTIVE DIRECTOR EFFECTIVE 1 SEPTEMBER 2026 BAT - JAVED IQBAL TO CONTINUE AS INTERIM CFO UNTIL 1 SEPT
04-09 14:07
BRIEF-Elevar Therapeutics Announces FDA Acceptance For Review Of New Drug Application For Lirafugratinib
BRIEF-Elevar Therapeutics Announces FDA Acceptance For Review Of New Drug Application For Lirafugratinib March 30 (Reuters) - ELEVAR THERAPEUTICS ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF NEW DRUG APPLICATION FOR LIRAFUGRATINIB AS SECOND-LINE CHOLANGIOCARCINOMA TREATMENT ELEVAR THERAPEUTICS: FDA GRANTE
03-30 20:04
BRIEF-Fennec Pharmaceuticals Announces Settlement Agreement Resolving Pedmark Patent Litigation
BRIEF-Fennec Pharmaceuticals Announces Settlement Agreement Resolving Pedmark Patent Litigation March 16 (Reuters) - Fennec Pharmaceuticals Inc FENC.O : FENNEC PHARMACEUTICALS ANNOUNCES SETTLEMENT AGREEMENT RESOLVING PEDMARK PATENT LITIGATION FENNEC PHARMACEUTICALS INC - CIPLA BARRED FROM MARKETING
03-16 20:20
BRIEF-Stellantis Announces Pricing Of Hybrid Bonds Offering
BRIEF-Stellantis Announces Pricing Of Hybrid Bonds Offering March 11 (Reuters) - Stellantis NV STLAM.MI : STELLANTIS ANNOUNCES PRICING OF HYBRID BONDS OFFERING €2.2 BILLION PERPETUAL FIXED RATE RESETTABLE CAPITAL SECURITIES, NON-CALL PERIOD OF 5.25 YEARS, PERPETUAL MATURITY, ANNUAL COUPON OF 6.250%
03-11 15:04
BRIEF-Spirit Airlines Says Co Issuing Recall Notices To Approximately 500 Pilots Who Were Involuntarily Furloughed Between Sept. 1, 2024, And Nov. 1, 2025
BRIEF-Spirit Airlines Says Co Issuing Recall Notices To Approximately 500 Pilots Who Were Involuntarily Furloughed Between Sept. 1, 2024, And Nov. 1, 2025 March 10 (Reuters) - Spirit Aviation Holdings Inc FLYYQ.PK : SPIRIT AIRLINES: ISSUING RECALL NOTICES TO APPROXIMATELY 500 PILOTS WHO WERE INVOLUN
03-10 21:08
BRIEF-Walker Lane Provides Update On Management Cease Trade Order
BRIEF-Walker Lane Provides Update On Management Cease Trade Order March 9 (Reuters) - Walker Lane Resources Ltd WLR.V : WALKER LANE PROVIDES UPDATE ON MANAGEMENT CEASE TRADE ORDER WALKER LANE RESOURCES LTD - CONTINUES WORK ON ANNUAL AUDITED FINANCIALS FOR FY ENDED SEPT 30, 2025 Source text: ID:nCNWD
03-09 19:11
BRIEF-Egetis Gets Notice Of Allowance For Patent In The U.S.
BRIEF-Egetis Gets Notice Of Allowance For Patent In The U.S. March 9 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST : RECEIVES NOTICE OF ALLOWANCE FOR MCT8 DEFICIENCY COMPOSITION PATENT IN THE U.S. ANTICIPATES REGULATORY DECISION ON NDA APPLICATION IN SEPTEMBER 2026 EXPECTS RESULTING PATENT WILL
03-09 14:03
